These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16221963)

  • 1. Toxicogenomics in risk assessment: applications and needs.
    Boverhof DR; Zacharewski TR
    Toxicol Sci; 2006 Feb; 89(2):352-60. PubMed ID: 16221963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Japanese toxicogenomics project: application of toxicogenomics.
    Uehara T; Ono A; Maruyama T; Kato I; Yamada H; Ohno Y; Urushidani T
    Mol Nutr Food Res; 2010 Feb; 54(2):218-27. PubMed ID: 20041446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of toxicogenomic data in risk assessment: a regulatory perspective.
    Chan VS; Theilade MD
    Clin Toxicol (Phila); 2005; 43(2):121-6. PubMed ID: 15822767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicogenomics in predictive toxicology in drug development.
    Suter L; Babiss LE; Wheeldon EB
    Chem Biol; 2004 Feb; 11(2):161-71. PubMed ID: 15123278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology.
    Heijne WH; Kienhuis AS; van Ommen B; Stierum RH; Groten JP
    Expert Rev Proteomics; 2005 Oct; 2(5):767-80. PubMed ID: 16209655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathway analysis tools and toxicogenomics reference databases for risk assessment.
    Ganter B; Zidek N; Hewitt PR; Müller D; Vladimirova A
    Pharmacogenomics; 2008 Jan; 9(1):35-54. PubMed ID: 18154447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future use of genomics data in toxicology: opportunities and challenges for regulatory applications.
    Goetz AK; Singh BP; Battalora M; Breier JM; Bailey JP; Chukwudebe AC; Janus ER
    Regul Toxicol Pharmacol; 2011 Nov; 61(2):141-53. PubMed ID: 21840362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicogenomics in the assessment of immunotoxicity.
    Baken KA; Vandebriel RJ; Pennings JL; Kleinjans JC; van Loveren H
    Methods; 2007 Jan; 41(1):132-41. PubMed ID: 17161310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of emerging technologies in toxicology and safety assessment: regulatory perspectives.
    Leighton JK
    Int J Toxicol; 2005; 24(3):153-5. PubMed ID: 16040567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of toxicogenomics to study mechanisms of genotoxicity and carcinogenicity.
    Ellinger-Ziegelbauer H; Aubrecht J; Kleinjans JC; Ahr HJ
    Toxicol Lett; 2009 Apr; 186(1):36-44. PubMed ID: 18822359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The state-of-the-art in predictive toxicogenomics.
    Fielden MR; Kolaja KL
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment.
    Wilson VS; Keshava N; Hester S; Segal D; Chiu W; Thompson CM; Euling SY
    Toxicol Appl Pharmacol; 2013 Sep; 271(3):299-308. PubMed ID: 21295051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database.
    Ganter B; Snyder RD; Halbert DN; Lee MD
    Pharmacogenomics; 2006 Oct; 7(7):1025-44. PubMed ID: 17054413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearing the standards landscape: the semantics of terminology and their impact on toxicogenomics.
    Burgoon LD
    Toxicol Sci; 2007 Oct; 99(2):403-12. PubMed ID: 17483496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating toxicogenomics into human health risk assessment: lessons learned from the benzo[a]pyrene case study.
    Chepelev NL; Moffat ID; Labib S; Bourdon-Lacombe J; Kuo B; Buick JK; Lemieux F; Malik AI; Halappanavar S; Williams A; Yauk CL
    Crit Rev Toxicol; 2015 Jan; 45(1):44-52. PubMed ID: 25605027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drivers of and Obstacles to the Adoption of Toxicogenomics for Chemical Risk Assessment: Insights from Social Science Perspectives.
    Pain G; Hickey G; Mondou M; Crump D; Hecker M; Basu N; Maguire S
    Environ Health Perspect; 2020 Oct; 128(10):105002. PubMed ID: 33112659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of toxicogenomics to genetic toxicology risk assessment.
    Thybaud V; Le Fevre AC; Boitier E
    Environ Mol Mutagen; 2007 Jun; 48(5):369-79. PubMed ID: 17567850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of toxicogenomics to drug development.
    Lakkis MM; DeCristofaro MF; Ahr HJ; Mansfield TA
    Expert Rev Mol Diagn; 2002 Jul; 2(4):337-45. PubMed ID: 12138498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.